It has been suggested that inactivating mutations in HNF1α and activating mutations in β-catenin within the hepatocellular adenomas serve to classify clinical and prognostic factors such as progression to carcinoma as proposed for β catenin mutations (43–45). Here, HNF1A is linked to hepatocellular adenoma.